#HepatocellularCarcinoma (HCC) is the most common type of adult primary #LiverCancer. The incidence of liver cancer is on the rise, highlighting the need for increased awareness, early detection and advanced treatment options. This #LiverCancerAwarenessMonth, we support those affected and advocate for further research. Learn more about how you can get involved: https://bit.ly/3V1r3LX
Omega Therapeutics
Biotechnology Research
Cambridge, Massachusetts 16,146 followers
Pioneering the first systematic approach to using mRNA as a new class of programmable epigenomic medicines.
About us
Omega Therapeutics is a clinical-stage biotechnology company pioneering the first systematic approach of using mRNA as programmable epigenomic medicines. Our OMEGA platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega’s engineered, modular, and programmable mRNA medicines, Omega Epigenomic Controllers™, target specific intervention points amongst the thousands of mapped and validated novel DNA-sequence-based epigenomic loci to durably tune single or multiple genes to treat and cure disease through unprecedented precision epigenomic control. Omega has a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.
- Website
-
http://www.omegatherapeutics.com
External link for Omega Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2017
Locations
-
Primary
20 Acorn Park Dr
STE 400
Cambridge, Massachusetts 02140, US
Employees at Omega Therapeutics
-
Joe Newman
-
Charles W. O'Donnell
Vice President, Head of Computational Genomics and Data Sciences at Omega Therapeutics
-
Michelle Werner
CEO at Alltrna and CEO/Partner at Flagship Pioneering
-
Eva Stroynowski Otte
Senior Vice President, Investor Relations and Corporate Affairs at Omega Therapeutics
Updates
-
#Omegan Kathleen Davenport will be participating in a panel about commercial and product strategy considerations in early R&D at the New Product Planning Summit by Fierce Life Sciences Events Watch her panel session here: https://bit.ly/3ZtQDxY
-
On #WorldCancerResearchDay, we join others in raising awareness of the ongoing urgent need for research to improve outcomes for patients living with cancer and provide hope to families. Find out how you can support here: https://bit.ly/48onmH2
-
🎯 Our epigenomic controllers are designed with unparalleled specificity. Each DNA-binding domain is engineered to target a single epigenomic zipcode or EpiZip, a unique ~20 nucleotide sequence, ensuring precise regulation of gene expression. Discover how we're harnessing the power of specificity to unlock new therapeutic possibilities: https://bit.ly/3xiJzZo
-
🔬 “We believe this publication, along with the promising preliminary clinical data generated from our ongoing MYCHELANGELO™ I trial, further validates the capabilities of the OMEGA platform to develop programmable epigenomic mRNA therapeutics to potentially address a broad spectrum of diseases.” - Mahesh Karande, President & CEO Preclinical data showing the ability of our #EpigenomicController to pre-transcriptionally regulate the MYC gene in models of hepatocellular carcinoma have been published in Nature Portfolio's Nature Communications! At Omega, we are committed to advancing scientific innovation and improving patient outcomes. Read more here: https://bit.ly/3ZtPypU
-
🎛️ Our #EpigenomicControllers can precisely tune gene expression to desired levels, offering a potentially revolutionary approach compared to current treatments. Unlike other methods, our technology can durably upregulate or downregulate the expression of genes, providing more targeted and effective options. Explore the future of #PrecisionEpigenomicControl with Omega Therapeutics: https://bit.ly/3xiJzZo
-
#DYK that globally there are more than 800 million adults living with #obesity? Treatments that are currently available may not be effective for every patient. At Omega, we’re partnering with Novo Nordisk to potentially advance the management of obesity through #PrecisionEpigenomicControl. Learn more here: https://bit.ly/4cgF53K
-
#Omegan Shengyan (Sandy) Liu, PhD, is sharing a presentation on lung-targeting LNPs at the 3rd Annual Next Gen LNP Delivery Summit. He will discuss how these cutting-edge advancements in pulmonary delivery technology are paving the way for transformative #mRNA treatments in respiratory diseases and beyond. Find out more about the Summit here: https://bit.ly/4dJSAdo
-
#MeetTheOmegans: Barbara Chan, CPA is our Senior Vice President of Finance & Chief Accounting Officer. With extensive experience in biotech industry finance and accounting, Barbara plays a crucial role in guiding our financial strategy. Her leadership and expertise are vital to our mission of advancing transformative epigenomic therapies. Learn more about Barbara here: https://bit.ly/4cnpBLs
-
We’re pleased to welcome Jennifer Nelson Ph.D., as Omega’s new Senior Vice President of Research. Her more than 20 years of experience and scientific expertise in #RNA biology will be crucial as we work to pioneer a new class of programmable #epigenomic mRNA medicines. Read more in our press release: https://bit.ly/3Alife9